Found 400 results
[ Author(Desc)] Keyword Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion, J Clin Oncol, vol. 12, pp. 2654-66, 1994.
E. Eisenhauer, Vermorken, J. B., and van Glabbeke, M., Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]., Ann Oncol, vol. 8, no. 10, pp. 963-8, 1997.
E. Eisenhauer, Bacon, M., Atri, M., M, L., R, N., P, P., E, S., A, F., and N, O., Radiologic review of response in ovarian cancer: Is it useful? Results from a joint European-Canadian trial. , Proc Am Soc Clin Oncol , vol. 13, 1994.
E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion., J Clin Oncol, vol. 12, no. 12, pp. 2654-66, 1994.
E. Eisenhauer and Vermorken, J. B., New drugs in gynecologic oncology., Curr Opin Oncol, vol. 8, no. 5, pp. 408-14, 1996.
E. Eisenhauer, Bacon, M., W, W., C, M. D., R, C., N, O., and Zee, B., Long term survivors from a European-Canadian Trial of paclitaxel in platinum-pretreated ovarian cancer. , Eur J Can , vol. 33, no. 8, 1997.
E. Eisenhauer, Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting., Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 74-5, 2008.
C. Elie, Geay, J. - F., Morcos, M., Le Tourneau, A., Girre, V., Broet, P., Marmey, B., Chauvenet, L., Audouin, J., Pujade-Lauraine, E., Camilleri-Broet, S., and Group, G. I. N. E. C. O., Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group), Br J Cancer, vol. 91, pp. 470-5, 2004.
G. Emile, Chauvenet, L., Tigaud, J. M., Chidiac, J., E. Lauraine, P., and Alexandre, J., A clinical experience of single agent bevacizumab in relapsing ovarian cancer, Gynecol Oncol, vol. 129, pp. 459-62, 2013.
G. Emons, Gorchev, G., Sehouli, J., Wimberger, P., Stähle, A., Hanker, L., Hilpert, F., Sindermann, H., Grundker, C., and Harter, P., Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the AGO-study group (AGO G, Gynecol Oncol, vol. 133, pp. 427-32, 2014.
A. Fagotti, Fanfani, F., Vizzielli, G., Gallotta, V., Ercoli, A., Paglia, A., Costantini, B., Vigliotta, M., Scambia, G., and Ferrandina, G., Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?, Gynecol Oncol, vol. 116, pp. 72-7, 2010.
C. Falandry, Rousseau, F., Mouret-Reynier, M. - A., Tinquaut, F., Lorusso, D., Herrstedt, J., Savoye, A. - M., Stefani, L., Bourbouloux, E., Sverdlin, R., D’Hondt, V., Lortholary, A., Brachet, P. - E., Zannetti, A., Malaurie, E., Venat-Bouvet, L., Trédan, O., Mourey, L., Pujade-Lauraine, E., and Freyer, G., Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer, JAMA Oncology, vol. 7, no. 6, p. 853, 2021.
F. Falcone, Maggiore, U. Leone Robe, Di Donato, V., Perrone, A. Myriam, Frigerio, L., Bifulco, G., Polterauer, S., Casadio, P., Cormio, G., Masciullo, V., Malzoni, M., and Greggi, S., Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study, Journal of Gynecologic Oncology, vol. 31, 2020.
G. Ferrandina, Ludovisi, M., Corrado, G., Carone, V., Petrillo, M., and Scambia, G., Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer, Gynecol Oncol, vol. 109, pp. 187-93, 2008.
J. M. Ferrero, Weber, B., Geay, J. - F., Lepille, D., Orfeuvre, H., Combe, M., Mayer, F., Leduc, B., Bourgeois, H., Paraiso, D., and Pujade-Lauraine, E., Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial, Ann Oncol, vol. 18, pp. 263-8, 2007.
G. F. Fleming, Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., and Burks, R. T., Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, vol. 22, pp. 2159-66, 2004.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial., Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
P. M. Flynn, Paul, J., Cruickshank, D. J., and Group, S. Gynaecolog, Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?, Gynecol Oncol, vol. 86, pp. 354-7, 2002.
G. Freyer, Geay, J. - F., Touzet, S., Provencal, J., Weber, B., Jacquin, J. P., Ganem, G., Tubiana-Mathieu, N., Gisserot, O., and Pujade-Lauraine, E., Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study, Ann Oncol, vol. 16, pp. 1795-800, 2005.
G. Freyer and Tinker, A. V., Clinical trials and treatment of the elderly diagnosed with ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 776-81, 2011.
M. Leonard Friedlander, Rau, J., Lee, C. Khoon, Meier, W., Lesoin, A., Kim, J. - W., Poveda, A. M., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. Trudy, Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., and A Bois, du, Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial., Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
M. Leonard Friedlander, Covens, A., Glasspool, R. M., Hilpert, F., Kristensen, G. B., Kwon, S., Selle, F., Small, W., Witteveen, E., and Russell, P., Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S78-82, 2014.
M. Leonard Friedlander, Trimble, E. L., Tinker, A., Alberts, D. S., Åvall-Lundqvist, E., Brady, M. F., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., Vergote, I. B., Beale, P., Bekkers, R., Calvert, P., Copeland, L., Glasspool, R. M., Gonzalez-Martin, A., Katsaros, D., Kim, J. Won, Miller, B., Provencher, D. M., Rubinstein, L., Atri, M., Zeimet, A. G., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., Clinical trials in recurrent ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 771-5, 2011.
M. Leonard Friedlander, Stockler, M., O'Connell, R., Voysey, M., Oza, A. M., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K. Marie, Butow, P., King, M. Trudy, and Group, S. Benefit St, Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer Intergroup symptom benefit study, Int J Gynecol Cancer, vol. 24, pp. 857-64, 2014.
M. Leonard Friedlander, Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., and Harnett, P., Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer, Int J Gynecol Cancer, vol. 17, pp. 350-8, 2007.